<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Oral and Cutaneous Lymphomas other than Mycosis Fungoides and Sézary Syndrome in a Mexican Cohort: Recategorization and Evaluation of International Geographical Disparities.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Oral and Cutaneous Lymphomas other than Mycosis Fungoides and Sézary Syndrome in a Mexican Cohort: Recategorization and Evaluation of International Geographical Disparities." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e36/5363139/06c1295ed2de/IJD-62-158-g007.jpg"/> </div> <div class="text-side"> <h1>Oral and Cutaneous Lymphomas other than Mycosis Fungoides and Sézary Syndrome in a Mexican Cohort: Recategorization and Evaluation of International Geographical Disparities.</h1> <p>Primary cutaneous extranodal natural killer/T-cell lymphoma. (a) Indurated and ulcerated erythematous plaque involving nose, left eyelids, and cheek, (b) diffuse dermal and subcutaneous infiltrate with prominent angiocentricity and angiodestruction (H and E, ×40), (c) immunopositivity with anti-CD3 antibodies (×100), (d) prominent expression of cytotoxic proteins (granzyme B) among neoplastic cells (×100), (e) strong immunoreactivity with anti-CD56 antibodies (×200), (f) nuclear expression of Epstein–Barr virus RNA by in situ hybridization (EBER, ×100)</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/28400635/" target="_blank">28400635</a></p><p>Type: Premalignant/Malignant, Category: Hematolymphoid</p>
</div> </div></div></body></html>